English 
Sound Wave Innovation, a startup originating from research at Tohoku University, has raised ¥2.65 billion in Series C funding as it prepares for the next stage of clinical testing for its dementia treatment technology.
The company is developing LIPUS-Brain, a device that uses low-intensity pulsed ultrasound to treat patients with early-stage Alzheimer’s disease and mild cognitive impairment. According to the company, the latest funding will support a pivotal clinical trial scheduled to run through 2026.
Several investors participated in the round, including Fiducia, Sumitomo Heavy Industries, iGlobe Partners, and other domestic and overseas backers. The size of the raise stands out at a time when many health tech startups are finding it difficult to secure large late-stage funding rounds.
A Different Path Than Traditional Drug Development
Most Alzheimer’s research has historically focused on pharmaceuticals. Sound Wave Innovation is pursuing a different route.
Its device delivers ultrasound waves through a wearable headset. The treatment is non-invasive and does not require surgery or anesthesia. Researchers believe the technology may help improve blood flow and circulation within the brain.
The approach has already attracted attention from regulators. Japan’s Ministry of Health, Labour and Welfare designated the device as the country’s first Breakthrough Medical Device in the dementia treatment category, giving the project additional visibility as it moves through clinical development.
こちらもお読みください： 日本写真医科テクノロジーズ、医療機器の小型化需要が高まる中、米国でマイクロモールド事業を拡大
Dementia Remains a Growing Challenge
The timing is hard to ignore.
Japan continues to face one of the most significant demographic shifts in the world. The country’s population is aging rapidly, and dementia cases are expected to increase in the years ahead. Healthcare systems, long-term care providers, and families are already dealing with the impact.
Any technology that shows potential in slowing cognitive decline or improving quality of life is likely to attract strong interest. That is one reason investors continue to watch the sector closely despite the long development timelines that often come with medical technologies.
University Research Is Reaching the Market
The funding round also highlights a broader trend taking place in Japan.
Universities are playing a larger role in startup creation than they did a decade ago. Research institutions that once focused almost entirely on academic work are now producing companies capable of attracting substantial private investment.
Sound Wave Innovation is one example of that shift. The company was built around research conducted by Professor Emeritus Hiroaki Shimokawa and his team at Tohoku University.
For Japan’s startup ecosystem, that matters. Policymakers and investors have spent years trying to strengthen the commercialization of university research. Deals like this suggest progress is being made.
Health Tech Is Drawing Interest Beyond Traditional Healthcare Investors
Another interesting detail is the participation of Sumitomo Heavy Industries.
The company is better known for its industrial and manufacturing businesses than for healthcare. Yet this is not an isolated case. Large Japanese corporations have increasingly started looking at healthcare and medical technology as potential growth areas.
For many industrial firms, demographic changes create opportunities that traditional markets may not. Medical devices, healthcare infrastructure, and age-related technologies are all attracting more attention than they did in the past.
That trend could create additional partnership opportunities between startups and established corporations looking for new revenue streams.
What This Could Mean for Japan’s Medical Device Industry
Clinical trials still need to be completed, and success is far from guaranteed. That remains the biggest hurdle.
Still, investors appear willing to support technologies that move beyond conventional pharmaceutical approaches.
If the device eventually reaches the market, it could encourage greater investment in non-invasive treatment technologies. It may also bring more attention to ultrasound-based therapies being explored for neurological and cardiovascular conditions.
The company has already indicated that its underlying technology could have applications beyond dementia, including severe angina and other heart-related disorders.
Opportunities Across the Healthcare Supply Chain
The effects would not be limited to one startup.
Medical device manufacturers, component suppliers, software developers, healthcare providers, contract manufacturers, and research organizations could all benefit if Japan’s medical device sector continues to expand.
The healthcare industry itself is changing. Devices are becoming more connected. Software is playing a larger role in treatment and monitoring. Artificial intelligence is increasingly being used to support diagnosis and clinical decision-making.
Those shifts are creating opportunities for businesses operating across multiple parts of the healthcare technology market.
For now, attention remains focused on the upcoming clinical trial. The results will determine whether Sound Wave Innovation can take the next step toward commercialization. But the funding round itself already says something important about where investment is flowing in Japan. Investors are showing a growing willingness to back medical technologies that combine university research, engineering expertise, and practical healthcare applications.
日本語